United States
MoglingBio Inc, founded in 2022, is a promising player in the Health Care industry, headquartered in the United States. The company's focus is on developing novel pharmacological approaches aimed at the rejuvenation of old stem cells. Its innovative angle presents a significant opportunity within the burgeoning field of regenerative medicine, potentially transforming treatment paradigms and enhancing longevity.
The company was last funded through a Seed Round investment on 26 October 2022, backed by Kizoo Technology Capital. This early-stage investment reflects Kizoo's confidence in the disruptive potential of MoglingBio's scientific approach and its market applications.
As the global healthcare landscape continues to evolve, MoglingBio is well-positioned to capitalize on increasing demand for regenerative and age-related treatments. For investors seeking exposure to cutting-edge biotechnology with long-term growth prospects, MoglingBio presents an enticing opportunity.
